Australia is eagerly anticipating the arrival of retatrutide, a novel dual GIP and GLP-1 receptor therapy, representing a significant advance in obesity treatment . Early clinical trials have demonstrated https://adrianavjbi072723.jiliblog.com/100167315/retatrutide-in-australia-a-potential-breakthrough-for-obesity-management